ATE199057T1 - Neue verwendung von diphenylbutyl- piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen - Google Patents

Neue verwendung von diphenylbutyl- piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen

Info

Publication number
ATE199057T1
ATE199057T1 AT92907159T AT92907159T ATE199057T1 AT E199057 T1 ATE199057 T1 AT E199057T1 AT 92907159 T AT92907159 T AT 92907159T AT 92907159 T AT92907159 T AT 92907159T AT E199057 T1 ATE199057 T1 AT E199057T1
Authority
AT
Austria
Prior art keywords
diphenylbutyl
treatment
toxic substances
disorders related
piperazine
Prior art date
Application number
AT92907159T
Other languages
English (en)
Inventor
Anders Bjoerk
Erik Christensson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE199057T1 publication Critical patent/ATE199057T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92907159T 1991-03-22 1992-03-23 Neue verwendung von diphenylbutyl- piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen ATE199057T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use
PCT/SE1992/000182 WO1992016211A1 (en) 1991-03-22 1992-03-23 New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (1)

Publication Number Publication Date
ATE199057T1 true ATE199057T1 (de) 2001-02-15

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907159T ATE199057T1 (de) 1991-03-22 1992-03-23 Neue verwendung von diphenylbutyl- piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen

Country Status (24)

Country Link
US (2) US5434156A (de)
EP (1) EP0538422B1 (de)
JP (1) JP3221611B2 (de)
KR (1) KR100196674B1 (de)
AT (1) ATE199057T1 (de)
AU (1) AU653797B2 (de)
BG (1) BG61829B1 (de)
BR (1) BR9204969A (de)
CA (1) CA2083505C (de)
CZ (1) CZ282222B6 (de)
DE (1) DE69231680T2 (de)
DK (1) DK0538422T3 (de)
EE (1) EE02973B1 (de)
ES (1) ES2154261T3 (de)
GR (1) GR3035805T3 (de)
HU (2) HU217833B (de)
IE (1) IE920920A1 (de)
NO (1) NO301311B1 (de)
PT (1) PT100279B (de)
RO (1) RO109702B1 (de)
RU (1) RU2095062C1 (de)
SE (1) SE9100860D0 (de)
SK (1) SK279237B6 (de)
WO (1) WO1992016211A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
ATE338575T1 (de) * 2001-01-17 2006-09-15 Hythiam Inc Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
JP4272885B2 (ja) * 2001-02-15 2009-06-03 ハイチアム,インコーポレイテッド コカイン依存症治療用薬剤
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2003066589A1 (en) 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (de) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
EP1858516A1 (de) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzungen zur behandlung und/oder verhinderung von depressionen
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1904182A2 (de) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Verfahren zur behandlung von drogenmissbrauch mit flibanserin
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2056797A2 (de) * 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
DE69231680T2 (de) 2001-06-07
DK0538422T3 (da) 2001-05-07
HU9203632D0 (en) 1993-03-29
CA2083505C (en) 2003-06-10
NO301311B1 (no) 1997-10-13
HUT64696A (en) 1994-02-28
US5618817A (en) 1997-04-08
KR930700108A (ko) 1993-03-13
US5434156A (en) 1995-07-18
JPH05507731A (ja) 1993-11-04
CZ344992A3 (en) 1994-02-16
WO1992016211A1 (en) 1992-10-01
AU1428092A (en) 1992-10-21
JP3221611B2 (ja) 2001-10-22
IE920920A1 (en) 1992-09-23
AU653797B2 (en) 1994-10-13
DE69231680D1 (de) 2001-03-15
EP0538422A1 (de) 1993-04-28
EE02973B1 (et) 1997-04-15
BR9204969A (pt) 1993-07-27
SK279237B6 (sk) 1998-08-05
RU2095062C1 (ru) 1997-11-10
PT100279A (pt) 1993-07-30
RO109702B1 (ro) 1995-05-30
BG97108A (bg) 1994-03-24
BG61829B1 (bg) 1998-07-31
HU217833B (hu) 2000-04-28
CA2083505A1 (en) 1992-09-23
KR100196674B1 (ko) 1999-06-15
EP0538422B1 (de) 2001-02-07
GR3035805T3 (en) 2001-07-31
CZ282222B6 (cs) 1997-06-11
PT100279B (pt) 1999-06-30
NO924502D0 (no) 1992-11-23
ES2154261T3 (es) 2001-04-01
SE9100860D0 (sv) 1991-03-22
NO924502L (no) 1992-11-23
SK344992A3 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
ATE199057T1 (de) Neue verwendung von diphenylbutyl- piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
DE69431601D1 (de) Neue verwendung von dexmedetomidin
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
DE69921662D1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
SG49239A1 (en) Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
KR940003550A (ko) 노인성 치매 예방 및 치료방법
KR930001908A (ko) 당뇨병에 있어서의 1,4-디히드로피리딘의 용도
ATE245432T1 (de) Verwendung von extrakten aus ginkgo-biloba- blättern zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee